Premium
MAP 30: a new inhibitor of HIV‐1 infection and replication
Author(s) -
Lee-Huang Sylvia,
Huang Philip L.,
Nara Peter L.,
Chen Hao-Chia,
Kung Hsiang-fu,
Huang Peter,
Huang Henry I.,
Huang Paul L.
Publication year - 1990
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(90)80438-o
Subject(s) - momordica , syncytium , reverse transcriptase , virology , viral replication , biology , human immunodeficiency virus (hiv) , virus , cytotoxic t cell , ribosome inactivating protein , microbiology and biotechnology , amino acid , chemistry , biochemistry , medicine , rna , in vitro , traditional medicine , ribosome , gene
A new inhibitor of human immunodeficiency virus (HIV) has been isolated and purified to homogeneity from the seeds and fruits of the Momordica charantia . This compound, MAP 30 (Momordica Anti‐HIV Protein), is a basic protein of about 30 kDa. It exhibits dose‐dependent inhibition of cell‐free HIV‐1 infection and replication as measured by: (i) quantitative focal syncytium formation on CEM‐ss monolayers; (II) viral core protein p24 expression; and (iii) viral‐associated reverse transcriptase (RT) activity in HIV‐1 infected H9 cells. The doses required for 50% inhibition (ID 50 ) in these assays were 0.83, 0.22 and 0.33 nM, respectively. No cytotoxic or cytostatic effects were found under the assay conditions. These data suggest that MAP 30 may be a useful therapeutic agent in the treatment of HIV‐1 infections. The sequence of the N‐terminal 44 amino acids of MAP 30 has been determined.